Literature DB >> 10093004

Cell death by overload of the elastin-laminin receptor on human activated lymphocytes: protection by lactose and melibiose.

G Péterszegi1, S Texier, L Robert.   

Abstract

BACKGROUND: Activated human lymphocytes were shown to express the elastin-laminin receptor in vitro and also in vivo in atherosclerotic plaques. In the presence of the agonist, elastin peptides, this receptor was shown to mediate an increased cell proliferation and an increased synthesis and excretion of an elastase-type serine endopeptidase. In this study, we investigated the variation of the above reaction as a function of agonist concentration.
MATERIALS AND METHODS: Human lymphocytes were obtained by tonsillectomy and cultured in the presence of phytohaemagglutinin and elastin peptides. Cell viability was evaluated by vital dye exclusion. Elastase and cathepsin G activities were determined in culture supernates and cell lysates using synthetic substrates. Apoptotic cells were identified by the TUNEL method and by electron microscopy.
RESULTS: At increasing concentrations of elastin peptides, a dose-dependent increase in cell death was observed. Up to 100 micrograms mL-1 elastin peptides and an increasing fraction of lymphocytes were found permeable to trypan blue, and a large proportion was in apoptosis. Elastin peptide-induced cell death was inhibited by 1 microgram mL-1 lactose and melibiose.
CONCLUSION: We describe here cell death of human activated lymphocytes expressing the elastin-laminin receptor in the presence of increasing concentrations of elastin peptides, agonists of the receptor. The mechanism of cell death appears to be related to the triggering of the release of elastase and free radicals mediated by the elastin-laminin receptor. Antagonists of this receptor, lactose and melibiose, protected the lymphocytes from the receptor-mediated cell death.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10093004     DOI: 10.1046/j.1365-2362.1999.00423.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  5 in total

Review 1.  Cellular and molecular mechanisms of aging and age related diseases.

Authors:  R Ladislas
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

2.  Inhibition of matrix metalloproteinase activity attenuates tenascin-C production and calcification of implanted purified elastin in rats.

Authors:  N Vyavahare; P L Jones; S Tallapragada; R J Levy
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

3.  Regulation of valvular interstitial cell calcification by adhesive peptide sequences.

Authors:  Xiaoxiao Gu; Kristyn S Masters
Journal:  J Biomed Mater Res A       Date:  2010-06-15       Impact factor: 4.396

4.  Structural characterization and in vivo pro-tumor properties of a highly conserved matrikine.

Authors:  Jordan Da Silva; Pedro Lameiras; Abdelilah Beljebbar; Alexandre Berquand; Matthieu Villemin; Laurent Ramont; Sylvain Dukic; Jean-Marc Nuzillard; Michael Molinari; Mathieu Gautier; Sylvie Brassart-Pasco; Bertrand Brassart
Journal:  Oncotarget       Date:  2018-04-03

Review 5.  The Elastin Receptor Complex: A Unique Matricellular Receptor with High Anti-tumoral Potential.

Authors:  Amandine Scandolera; Ludivine Odoul; Stéphanie Salesse; Alexandre Guillot; Sébastien Blaise; Charlotte Kawecki; Pascal Maurice; Hassan El Btaouri; Béatrice Romier-Crouzet; Laurent Martiny; Laurent Debelle; Laurent Duca
Journal:  Front Pharmacol       Date:  2016-03-04       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.